Euroapi SAS (EAPI) - Net Assets
Based on the latest financial reports, Euroapi SAS (EAPI) has net assets worth €953.40 Million EUR (≈ $1.11 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.44 Billion ≈ $1.69 Billion USD) and total liabilities (€488.50 Million ≈ $571.11 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Euroapi SAS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €953.40 Million |
| % of Total Assets | 66.12% |
| Annual Growth Rate | -0.69% |
| 5-Year Change | -0.6% |
| 10-Year Change | N/A |
| Growth Volatility | 9.1 |
Euroapi SAS - Net Assets Trend (2019–2024)
This chart illustrates how Euroapi SAS's net assets have evolved over time, based on quarterly financial data. Also explore EAPI current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Euroapi SAS (2019–2024)
The table below shows the annual net assets of Euroapi SAS from 2019 to 2024. For live valuation and market cap data, see EAPI market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €983.50 Million ≈ $1.15 Billion |
+6.01% |
| 2023-12-31 | €927.70 Million ≈ $1.08 Billion |
-16.44% |
| 2022-12-31 | €1.11 Billion ≈ $1.30 Billion |
+9.76% |
| 2021-12-31 | €1.01 Billion ≈ $1.18 Billion |
+2.23% |
| 2020-12-31 | €989.40 Million ≈ $1.16 Billion |
-2.82% |
| 2019-12-31 | €1.02 Billion ≈ $1.19 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Euroapi SAS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 156420000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €701.50 Million | 71.33% |
| Common Stock | €95.60 Million | 9.72% |
| Other Components | €186.40 Million | 18.95% |
| Total Equity | €983.50 Million | 100.00% |
Euroapi SAS Competitors by Market Cap
The table below lists competitors of Euroapi SAS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Laramide Resources Ltd
AU:LAM
|
$152.52 Million |
|
Hyundai Pharm
KO:004310
|
$152.68 Million |
|
Modiv Inc
NYSE:MDV
|
$152.69 Million |
|
Ryvu Therapeutics SA
WAR:RVU
|
$152.71 Million |
|
Duta Intidaya Tbk PT
JK:DAYA
|
$152.47 Million |
|
msg life ag
HM:MSGL
|
$152.38 Million |
|
Condor Energies Inc.
TO:CDR
|
$152.35 Million |
|
Huangshan Tourism Development Co Ltd B
SHG:900942
|
$152.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Euroapi SAS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 927,700,000 to 983,500,000, a change of 55,800,000 (6.0%).
- Net loss of 130,600,000 reduced equity.
- Share repurchases of 100,000 reduced equity.
- Other comprehensive income decreased equity by 6,700,000.
- Other factors increased equity by 193,200,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-130.60 Million | -13.28% |
| Share Repurchases | €100.00K | -0.01% |
| Other Comprehensive Income | €-6.70 Million | -0.68% |
| Other Changes | €193.20 Million | +19.64% |
| Total Change | €- | 6.01% |
Book Value vs Market Value Analysis
This analysis compares Euroapi SAS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €10.83 | €1.37 | x |
| 2020-12-31 | €10.52 | €1.37 | x |
| 2021-12-31 | €10.76 | €1.37 | x |
| 2022-12-31 | €11.75 | €1.37 | x |
| 2023-12-31 | €9.85 | €1.37 | x |
| 2024-12-31 | €10.41 | €1.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Euroapi SAS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.21%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.51x
- Recent ROE (-13.28%) is below the historical average (-6.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.25% | 0.27% | 0.58x | 1.55x | €-99.31 Million |
| 2020 | -0.64% | -0.67% | 0.59x | 1.62x | €-105.24 Million |
| 2021 | -0.80% | -0.91% | 0.55x | 1.60x | €-109.25 Million |
| 2022 | -1.35% | -1.53% | 0.57x | 1.56x | €-126.02 Million |
| 2023 | -20.45% | -18.62% | 0.63x | 1.74x | €-282.47 Million |
| 2024 | -13.28% | -14.21% | 0.62x | 1.51x | €-228.95 Million |
Industry Comparison
This section compares Euroapi SAS's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $444,946,750
- Average return on equity (ROE) among peers: 2.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Euroapi SAS (EAPI) | €953.40 Million | 0.25% | 0.51x | $152.50 Million |
| AB Science S.A (AB) | $-23.75 Million | 0.00% | 0.00x | $81.71 Million |
| Boiron SA (BOI) | $505.46 Million | 8.04% | 0.51x | $456.63 Million |
| Ipsen SA (IPN) | $926.25 Million | -3.18% | 0.69x | $10.50 Billion |
| Vetoquinol (VETO) | $371.83 Million | 5.17% | 0.74x | $1.02 Billion |
About Euroapi SAS
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry;… Read more